Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis

Oncogene volume 32, pages 4064–4077 (2013)Cite this article

Subjects

Abstract

Metastasis, which remains incompletely characterized at the molecular and biochemical levels, is a highly specific process. Despite the ability of disseminated cancer cells to intravasate into distant tissues, it has been long recognized that only a limited subset of target organs develop clinically overt metastases. Therefore, subsequent adaptation of disseminated cancer cells to foreign tissue microenvironment determines the metastatic latency and tissue tropism of these cells. As a result, studying interactions between the disseminated cancer cells and the adjacent stromal cells will provide a better understanding of what constitutes a favorable or unfavorable microenvironment for disseminated cancer cells in a tissue-specific manner. Previously, we reported a protein signature of brain metastasis showing increased ability of brain metastatic breast cancer cells to counteract oxidative stress. In this study, we showed that another protein from the brain metastatic protein signature, neurotrophin-3 (NT-3), has a dual function of regulating the metastatic growth of metastatic breast cancer cells and reducing the activation of immune response in the brain. More importantly, increased NT-3 secretion in metastatic breast cancer cells results in a reversion of mesenchymal-like (EMT) state to epithelial-like (MET) state and vice versa. Ectopic expression of NT-3 in EMT-like breast cancer cells reduces their migratory ability and increases the expression of HER2 (human epidermal growth factor receptor 2) and E-cadherin at the cell–cell junction. In addition, both endogenous and ectopic expression of NT-3 reduced the number of fully activated cytotoxic microglia. In summary, NT-3 appears to promote growth of metastatic breast cancer cells in the brain by facilitating the re-epithelialization of metastatic breast cancer cells and downmodulating the cytotoxic response of microglia. Most importantly, our results provide new insights into the latency and development of central nervous system macrometastases in patients with HER2-positive breast tumors and provide mechanistic rationale to target HER2 signaling for HER2-positive breast cancer brain metastasis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Welch DR, Steeg PS, Rinker-Schaeffer CW . Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res 2000; 2: 408–416.

    Article  CAS  Google Scholar 

  2. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS . Breast cancer metastasis to the central nervous system. Am J Pathol 2005; 167: 913–920.

    Article  CAS  Google Scholar 

  3. Price JE . Metastasis from human breast cancer cell lines. Breast Cancer Res Treat 1996; 39: 93–102.

    Article  CAS  Google Scholar 

  4. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518–524.

    Article  CAS  Google Scholar 

  5. Lu X, Kang Y . Organotropism of breast cancer metastasis. J Mammary Gland Biol Neoplasia 2007; 12: 153–162.

    Article  Google Scholar 

  6. Ohno S, Ishida M, Kataoka A, Murakami S . Brain metastasis of breast cancer. Breast Cancer 2004; 11: 27–29.

    Article  Google Scholar 

  7. Kirsch DG, Loeffler JS . Brain metastases in patients with breast cancer: new horizons. Clin Breast Cancer 2005; 6: 115–124.

    Article  Google Scholar 

  8. Chang EL, Lo S . Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 2003; 8: 398–410.

    Article  Google Scholar 

  9. Puduvalli VK . Brain metastases: biology and the role of the brain microenvironment. Curr Oncol Rep 2001; 3: 467–475.

    Article  CAS  Google Scholar 

  10. Nathoo N, Chahlavi A, Barnett GH, Toms SA . Pathobiology of brain metastases. J Clin Pathol 2005; 58: 237–242.

    Article  CAS  Google Scholar 

  11. Tomasevic Z, Radosevic-Jelic L, Jovanovic D, Milovanovic Z, Tomasevic ZM, Jelic S et al. Brain metastases as late breast cancer relapse. Single institution experience and review of the literature. J BUON 2009; 14: 225–228.

    CAS  PubMed  Google Scholar 

  12. Piccirilli M, Sassun TE, Brogna C, Giangaspero F, Salvati M . Late brain metastases from breast cancer: clinical remarks on 11 patients and review of the literature. Tumori 2007; 93: 150–154.

    Article  Google Scholar 

  13. Chen EI, Hewel J, Krueger JS, Tiraby C, Weber MR, Kralli A et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res 2007; 67: 1472–1486.

    Article  CAS  Google Scholar 

  14. Huang EJ, Reichardt LF . Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003; 72: 609–642.

    Article  CAS  Google Scholar 

  15. Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, Romon R et al. Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Res 2008; 68: 346–351.

    Article  CAS  Google Scholar 

  16. Descamps S, Pawlowski V, Revillion F, Hornez L, Hebbar M, Boilly B et al. Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Res 2001; 61: 4337–4340.

    CAS  Google Scholar 

  17. Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Berteaux N et al. Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Clin Cancer Res 2011; 17: 1741–1752.

    Article  CAS  Google Scholar 

  18. Hondermarck H . Nerve growth factor: the dark side of the icon. Am J Pathol 2008; 172: 865–867.

    Article  Google Scholar 

  19. Kowalski PJ, Rubin MA, Kleer CG . E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003; 5: R217–R222.

    Article  CAS  Google Scholar 

  20. Chao YL, Shepard CR, Wells A . Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 2010; 9: 179.

    Article  Google Scholar 

  21. Chaffer CL, Dopheide B, McCulloch DR, Lee AB, Moseley JM, Thompson EW et al. Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder. Clin Exp Metastasis 2005; 22: 115–125.

    Article  CAS  Google Scholar 

  22. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED . Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006; 66: 11271–11278.

    Article  CAS  Google Scholar 

  23. Yates CC, Shepard CR, Stolz DB, Wells A . Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer 2007; 96: 1246–1252.

    Article  CAS  Google Scholar 

  24. Oltean S, Sorg BS, Albrecht T, Bonano VI, Brazas RM, Dewhirst MW et al. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci USA 2006; 103: 14116–14121.

    Article  CAS  Google Scholar 

  25. Vincan E, Darcy PK, Smyth MJ, Thompson EW, Thomas RJ, Phillips WA et al. Frizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growth. Differentiation 2005; 73: 142–153.

    Article  CAS  Google Scholar 

  26. He BP, Wang JJ, Zhang X, Wu Y, Wang M, Bay BH et al. Differential reactions of microglia to brain metastasis of lung cancer. Mol Med 2006; 12: 161–170.

    Article  CAS  Google Scholar 

  27. Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis 2008; 25: 799–810.

    Article  Google Scholar 

  28. Tzeng SF, Huang HY, Lee TI, Jwo JK . Inhibition of lipopolysaccharide-induced microglial activation by preexposure to neurotrophin-3. J Neurosci Res 2005; 81: 666–676.

    Article  CAS  Google Scholar 

  29. Elkabes S, DiCicco-Bloom EM, Black IB . Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. J Neurosci 1996; 16: 2508–2521.

    Article  CAS  Google Scholar 

  30. Tagliabue E, Castiglioni F, Ghirelli C, Modugno M, Asnaghi L, Somenzi G et al. Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells. J Biol Chem 2000; 275: 5388–5394.

    Article  CAS  Google Scholar 

  31. Matsumura H, Ohnishi T, Kanemura Y, Maruno M, Yoshimine T . Quantitative analysis of glioma cell invasion by confocal laser scanning microscopy in a novel brain slice model. Biochem Biophys Res Commun 2000; 269: 513–520.

    Article  CAS  Google Scholar 

  32. Jung S, Kim HW, Lee JH, Kang SS, Rhu HH, Jeong YI et al. Brain tumor invasion model system using organotypic brain-slice culture as an alternative to in vivo model. J Cancer Res Clin Oncol 2002; 128: 469–476.

    Article  Google Scholar 

  33. Cho S, Wood A, Bowlby MR . Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics. Curr Neuropharmacol 2007; 5: 19–33.

    Article  CAS  Google Scholar 

  34. Menon MB, Ronkina N, Schwermann J, Kotlyarov A, Gaestel M . Fluorescence-based quantitative scratch wound healing assay demonstrating the role of MAPKAPK-2/3 in fibroblast migration. Cell Motil Cytoskeleton 2009; 66: 1041–1047.

    Article  CAS  Google Scholar 

  35. Yarrow JC, Perlman ZE, Westwood NJ, Mitchison TJ . A high-throughput cell migration assay using scratch wound healing, a comparison of image-based readout methods. BMC Biotechnol 2004; 4: 21.

    Article  Google Scholar 

  36. Louie E, Nik S, Chen JS, Schmidt M, Song B, Pacson C et al. Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res 2010; 12: R94.

    Article  CAS  Google Scholar 

  37. Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T et al. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 2010; 116: 302–308.

    Article  Google Scholar 

  38. Perry VH, Cunningham C, Holmes C . Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007; 7: 161–167.

    Article  CAS  Google Scholar 

  39. Ohsawa K, Imai Y, Sasaki Y, Kohsaka S . Microglia/macrophage-specific protein Iba1 binds to fimbrin and enhances its actin-bundling activity. J Neurochem 2004; 88: 844–856.

    Article  CAS  Google Scholar 

  40. Klos KJ, O’Neill BP . Brain metastases. Neurologist 2004; 10: 31–46.

    Article  Google Scholar 

  41. Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, Choi YJ et al. Clinical outcomes and breast cancer subtypes in patients with brain metastases. Onkologie 33: 146–152.

    Article  Google Scholar 

  42. Trimboli AJ, Fukino K, de Bruin A, Wei G, Shen L, Tanner SM et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 2008; 68: 937–945.

    Article  CAS  Google Scholar 

  43. Tse JC, Kalluri R . Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 2007; 101: 816–829.

    Article  CAS  Google Scholar 

  44. Montel V, Huang TY, Mose E, Pestonjamasp K, Tarin D . Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model. Am J Pathol 2005; 166: 1565–1579.

    Article  CAS  Google Scholar 

  45. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 58–68.

    Article  Google Scholar 

  46. Mehlen P, Puisieux A . Metastasis: a question of life or death. Nat Rev Cancer 2006; 6: 449–458.

    Article  CAS  Google Scholar 

  47. Kim JW, Wong CW, Goldsmith JD, Song C, Fu W, Allion MB et al. Rapid apoptosis in the pulmonary vasculature distinguishes non-metastatic from metastatic melanoma cells. Cancer Lett 2004; 213: 203–212.

    Article  CAS  Google Scholar 

  48. MacDonald IC, Groom AC, Chambers AF . Cancer spread and micrometastasis development: quantitative approaches for in vivo models. Bioessays 2002; 24: 885–893.

    Article  CAS  Google Scholar 

  49. Choi YH, Ahn JH, Kim SB, Jung KH, Gong GY, Kim MJ et al. Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Ann Oncol 2009; 20: 1337–1343.

    Article  CAS  Google Scholar 

  50. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972–2977.

    Article  Google Scholar 

  51. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26: 1993–1999.

    Article  CAS  Google Scholar 

  52. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533–543.

    Article  CAS  Google Scholar 

  53. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733–2743.

    Article  CAS  Google Scholar 

  54. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007; 67: 4190–4198.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants to EIC from the Susan Komen Foundation and the Mary Anita Conroy Memorial Breast Cancer Fund from the Manhasset Women’s Coalition Against Breast Cancer. S Tsirka and K Ji were supported by R01NS42168.

Author information

Authors and Affiliations

  1. Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA

    E Louie, X F Chen, A Coomes, K Ji, S Tsirka & E I Chen

Authors
  1. E Louie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X F Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Coomes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Tsirka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E I Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E I Chen.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Louie, E., Chen, X., Coomes, A. et al. Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis. Oncogene 32, 4064–4077 (2013). https://doi.org/10.1038/onc.2012.417

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2012.417

Keywords

This article is cited by

Search

Advanced search

Quick links